Vitiligo Treatment Market Research, 2031
The global vitiligo treatment market size was valued at $410.5 million in 2021, and is projected to reach $625.8 million by 2031, growing at a CAGR of 4.3% from 2022 to 2031. Vitiligo is a disease that causes the loss of skin color in blotches. Vitiligo occurs when pigment-producing cells die or stop functioning. Loss of skin color can affect any part of the body, including the mouth, hair, hands, neck, and eyes. It is caused by the lack of a pigment called melanin in the skin. Melanin is a pigment produced by skin cells known as melanocytes, and it gives color to the skin.
In vitiligo, there are not enough working melanocytes to produce enough melanin in your skin. This causes white patches to develop on your skin or hair. Vitiligo does not have serious side-effects to patient’s health, however it can result in physical complications, such as eye problems, hearing problems, and sunburn. Furthermore, people with vitiligo also tend to be more likely to have another autoimmune disease such as thyroid problems and some types of anemia. There is no permanent cure for vitiligo and it is a lifelong condition. It is not contagious in nature. The treatment options may include topical and systemic corticosteroid, calcineurin inhibitors, and tricyclic antidepressants.
The growth of global vitiligo treatment market size is majorly driven by rise in the number of people suffering from vitiligo. For instance, according to Global Vitiligo Foundation in 2021, approximately 70 million people across the globe have vitiligo among them 20-30% of patients are children. The rising need for new treatment options for vitiligo conditions, with a motive to gain regulatory approval for vitiligo treatment is expected to contribute towards the growth of the market.
Furthermore, market key players are focused on developing new vitiligo treatment options, to improve potency and outcomes of therapies in the affected population. In addition, increase in awareness about vitiligo conditions among developed and developing countries such as U.S., Germany, Japan, and India propel the growth of the market.
Increase in prevalence of non-segmental vitiligo is the key factor contribute towards the growth of the market. For instance, according to National Library of Medicine in 2020, non-segmental vitiligo is the most common type of vitiligo affecting 0.77% people across the globe.
In addition, increase in R&D activities for developing innovative therapies by key players such as Incyte Corporation, Pfizer Inc, Mylan N.V., and Astellas Pharma will provide opportunities for the market growth during the forecast period. Moreover, rise in healthcare expenditure also provides vitiligo treatment market opportunity for the growth of the market.
Furthermore, increase in awareness about treatments for vitiligo propels the demand for vitiligo therapies. However, high cost of treatments and side-effects associated with medications negatively impact the vitiligo treatment market growth. For instance, prolonged use of topical corticosteroids can cause burning and stinging sensation.
Moreover, the global market expansion is being fueled by factors, such as rise in patients seeking treatments for vitiligo conditions, and rise in healthcare expenditure in developing countries such as India and China. Moreover, increase in adoption of different strategies such as product launch, collaboration, and partnership among the key players in the field of vitiligo therapies propel the growth of the global vitiligo treatment market. For instance, Arcutis collaborated with Jiangsu Hengrui Medicine CO., Ltd. for an exclusive license to the active pharmaceutical ingredient in ARQ-252, a potent and highly selective inhibitor of janus kinase type 1 (JAK1), for all topical dermatological uses in the United States, Canada, Europe, and Japan.
Impact of COVID-19 on Market
The outbreak of COVID-19 has disrupted workflows in the health care sector around the world. Nearly all industries have been impacted by COVID-19 including vitiligo treatment industry. Coronavirus crises led to strictly follow the social distancing rules, and visit hospitals only for emergency need have resulted in a significant decline in demand for the vitiligo treatment. For instance, according to the Commonwealth Fund, it was estimated that there was nearly 60% initial decrease in overall outpatient visits by May 2020 due to COVID-19. This was expected to negatively affect the demand for vitiligo treatment for surgeries. The outbreak of COVID-19 impacted the market, as hospital and healthcare services were significantly reduced due to social distancing measures taken by governments to stop COVID-19 spread.
The overall impact of COVID-19 pandemic remained negative for key players in the vitiligo treatment industry. For instance, according to National Library of Medicine corticosteroid demand has significantly decreased during the COVID-19 pandemic. The routine treatments are delayed to some extent during the pandemic as seeking treatments from hospitals was at risk of infection. However, the market is anticipated to witness recovery in 2021 and beyond, and show stable growth for vitiligo treatments in the coming future.
Vitiligo Treatment Market Segmentation
The vitiligo treatment market is segmented on the basis of drug class type, type, distribution channel, and region. By drug class type, it is fragmented into corticosteroids, calcineurin inhibitor, and others. By type, it is divided into segmental and non-segmental. By distribution channel, it is segregated into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region-wise, the market is studies across North America, Europe, Asia-Pacific, and LAMEA.
Drug Class Type Segment Review
By drug class type, the corticosteroid segment has highest vitiligo treatment market share in 2021, due to various advantages of corticosteroids such as anti-inflammatory property, slow the progression of vitiligo, and dermatologist prescribe the corticosteroids as first line therapy. In addition, it is the fastest growing segment in between 2022-2031, due to rise in patients seeking treatment for vitiligo.
By Drug Class Type
The Corticosteroids segment dominated the market in 2021.
Type Segment Review
By type, the non-segmental segment dominated the market in terms of revenue in 2021 and is expected to continue this trend during the forecast period, due to rise in patients diagnosed with the non-segmental vitiligo. In addition, it is the fastest growing segment in between 2022-2031, due to increase in awareness about the symptoms and causes of vitiligo condition.
By Type
The non-segmental segment dominated the market in 2021.
Distribution Channel Segment Review
By distribution channel, the drug stores and retail pharmacies segment dominated the market in terms of revenue in 2021, due to increase in prescription drug sell and shift of patient preference to buy medicine from the retail pharmacy stores. On the other hand, online providers segment expected to witness a considerable growth from 2022 to 2031, due to rise in E-Pharmacy websites, most convenient way to buy medicine, and huge discounts offered by the online medicine providers.
By Distribution Channel
The Drug Stores and Retail Pharmacies segment dominated the market in 2021.
Regional Segment Review
The North America market acquired largest vitiligo treatment market share in 2021, due to well established healthcare infrastructure, availability of advanced therapies and strong presence of key players in this region. On the other hand, Asia-Pacific expected to witness a considerable growth from 2022 to 2031, due to rise in healthcare expenditure, high patient pool among China and India, and rise in research and development activities in pharmaceutical sector.
By Region
North America dominated the market in 2021 and is expected to grow at a CAGR of 3.4%.
Competitive Analysis
Some of the major companies that operate in the global vitiligo treatment market include, Arcutis Biotherapeutics, Astellas Pharma Inc., Bausch Health Companies Inc. (Bausch+Lomb Inc.), Bristol-Mayers Squibb (Celegen), Dermavant Science Inc., Dr. Reddy’s Laboratories Ltd, Incyte Corporation, Merck kGaA, Pfizer Inc., Viatirs Inc. (Mylan N.V.).
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vitiligo treatment market analysis from 2021 to 2031 to identify the prevailing vitiligo treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the vitiligo treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global vitiligo treatment market trends, key players, market segments, application areas, and market growth strategies.
Vitiligo Treatment Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 625.8 million |
 Growth Rate | CAGR of 4.3% |
 Forecast period | 2021 - 2031 |
 Report Pages | 270 |
 By Type |
|
 By Distribution Channel |
|
 By Drug Class Type |
|
 By Region |
|
 Key Market Players | Glenmark Pharmaceuticals Ltd, Dr. Reddy’s Laboratories Ltd, Belcher Pharmaceuticals, LCC, Mylan N.V., Celgene Corporation, Strides Pharma Science Limited, Arcutis Biotherapeutics, Astellas Pharma Inc., Panacea Biotec Ltd, clinuvel pharmaceuticals ltd, Bausch Health Companies Inc., Pfizer Inc. |
Analyst Review
The global vitiligo treatment market is expected to exhibit high growth potential attributable to factors such as increase in prevalence of vitiligo conditions, rise in R&D activities in pharmaceutical industry for manufacturing novel therapies for vitiligo, and surge in number of approvals by U.S. Food and Drug Administration (FDA) for drug treatments. Moreover, increase in awareness about vitiligo and its treatment among developing countries such as India and China contribute toward the growth of the market.
North America is expected to witness the highest growth, in terms of revenue, owing to rise in prevalence of non-segmental vitiligo, availability of treatments, and strong presence of key players. However, Asia-Pacific is expected to register fastest CAGR during the forecast period due to rise in awareness about the vitiligo conditions and increase in healthcare expenditure.
The base year is 2021 in vitiligo treatment market.
Corticosteroid is the most influencing segment in vitiligo treatment market which is attributed to rise in demand for corticosteroids as it shows significant result in non-segmental vitiligo treatment.
Top companies such as, Bausch Health Companies Inc. (Bausch+Lomb Inc.), Astellas Pharma, Dr. Reddy’s Laboratories Ltd and Incyte Corporation held a high market position in 2020. These key players held a high market position owing to the strong geographical foothold in different regions.
The major factor that fuels the growth of the vitiligo treatment market are increase in prevalence of vitiligo, rise in demand for advanced and effective treatment, and increase in healthcare spending.
The market value of vitiligo treatment market in 2031 is $625.82 million
Vitiligo treatments are the medications used to treat segmental and non-segmetal vitiligo conditions.
The forecast period for vitiligo treatment market is 2022 to 2031
The total market value of vitiligo treatment market is $410.54 million in 2021.
Loading Table Of Content...
